Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult)
Open Access
- 1 August 2001
- journal article
- review article
- Published by American Diabetes Association in Diabetes Care
- Vol. 24 (8), 1460-1467
- https://doi.org/10.2337/diacare.24.8.1460
Abstract
Type 1 diabetes is caused by the immune-mediated destruction of islet insulin-secreting β-cells. This chronic destructive process is associated with both cellular and humoral immune changes in the peripheral blood that can be detected months or even years before the onset of clinical diabetes. Throughout this prediabetic period, metabolic changes, including altered glucose tolerance and reduced insulin secretion, deteriorate at variable rates and eventually result in clinical diabetes. A fraction of individuals with humoral immunological changes have clinical diabetes that initially is not insulin-requiring. The onset of diabetes in these patients is usually in adult life, and because their diabetes is at least initially not insulin-requiring, they appear clinically to be affected by type 2 diabetes. Such patients probably have the same disease process as patients with type 1 diabetes in that they have similar HLA genetic susceptibility as well as autoantibodies to islet antigens, low insulin secretion, and a higher rate of progression to insulin dependency. These patients are defined as being affected by an autoimmune type of diabetes not requiring insulin at diagnosis, which is also named latent autoimmune diabetes of the adult (LADA). Special attention should be paid to diagnose such patients because therapy may influence the speed of progression toward insulin dependency, and in this respect, efforts should be made to protect residual C-peptide secretion. LADA can serve as a model for designing new strategies for prevention of type 1 diabetes but also as a target group for prevention in its own right.Keywords
This publication has 66 references indexed in Scilit:
- Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry.Diabetes Care, 2000
- Insulin and Glucagon Secretion in Patients with Slowly Progressing Autoimmune Diabetes (LADA)Journal of Clinical Endocrinology & Metabolism, 2000
- Troglitazone Exhibits Immunomodulatory Activity on the Cytokine Production of Activated Human LymphocytesHormone and Metabolic Research, 1999
- Metformin Does Not Alter Diabetes Incidence in the NOD MouseHormone and Metabolic Research, 1997
- Meta-Analysis of Nicotinamide Treatment in Patients With Recent-Onset IDDMDiabetes Care, 1996
- Antibody to the Mr 65,000 Isoform of Glutamic Acid Decarboxylase are Detected in Non-Insulin-Dependent Diabetes in JapaneseJournal of Autoimmunity, 1996
- The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVI. The relationship of C-peptide to the incidence and progression of diabetic retinopathyDiabetes, 1995
- Type I Diabetes Masquerading as Type II Diabetes: Possible implications for prevention and treatmentDiabetes Care, 1994
- Oral Hypoglycemic AgentsThe New England Journal of Medicine, 1989
- A Comparison of Childhood and Adult Type I Diabetes MellitusThe New England Journal of Medicine, 1989